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Atrial fibrillation (AF) is associated with increased risk for stroke and systemic embolism. There is plausible evi-
dence linking inflammation to the initiation and perpetuation of AF and AF-related thrombosis. Various inflam-
matory markers (C-reactive protein, tumor necrosis factor-, interleukin-2, interleukin-6, and interleukin-8) have
been associated with AF. Proposed mechanisms linking inflammation and the prothrombotic AF state include
endothelial activation/damage, production of tissue factor from monocytes, increased platelet activation, and
increased expression of fibrinogen. The present review aims to provide an update on the association of inflam-
mation and AF, including the impact of inflammatory markers on clinical presentation and outcome of AF
patients. (J Am Coll Cardiol 2012;60:2263–70) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.063The pathophysiology of atrial fibrillation (AF) is complex
and incompletely understood. Several studies have described
an association between AF and abnormal prothrombotic
plasma markers, including fibrinogen, von Willebrand fac-
tor (vWF), and soluble P-selectin, suggesting that the
arrhythmia itself contributes to the development of a pro-
thrombotic state (1). Furthermore, various inflammatory
markers and mediators such as C-reactive protein (CRP),
tumor necrosis factor (TNF)-, interleukin (IL)-2, IL-6,
IL-8, and monocyte chemoattractant protein (MCP)-1
have been linked with the presence or the outcome of AF
(2). Finally, recent studies indicate that activated inflamma-
tory cells and inflammatory mediators may confer a pro-
thrombotic state by promoting endothelial damage/
dysfunction and platelet activation in patients with AF, thus
linking inflammation and thrombosis.
In the present review article, we summarize the available
data on the potential mechanisms linking inflammation to
AF and to AF-related thrombosis. Current research in this
field mainly focuses on the impact of inflammatory markers
on clinical presentation and outcome of AF and it further
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accepted April 1, 2012.aims to address four important questions. 1) Is inflamma-
tion a consequence or a cause of AF? 2) Is inflammation
related to AF a systemic or local phenomenon? 3) Could
inflammation reflect underlying disease not associated with
AF per se? 4) What role does inflammation play in
thromboembolism in the setting of AF?
Search Strategy
We searched PubMed database between January 1990 and
December 2011 with the following terms individually or in
combination: “atrial fibrillation,” “inflammation,” “interleu-
kin,” “chemokine,” “IL-2,” “IL-6,” “IL-8,” “CRP,” “TNF-
,” “MCP-1,” and “prothrombotic state.” References from
the relevant articles were reviewed, and related articles were
identified.
Inflammatory Markers and Atrial Fibrillation
Leukocyte activation is considered an important inflamma-
tory pathway underlying AF (3). Cytokines and chemo-
kines orchestrate leukocyte trafficking and activation and
have been assessed as potential mediators in the estab-
lishment and perpetuation of AF and AF-related throm-
bosis (Online Refs. 1–5). The source, biological effect,
and prognostic role of the main inflammatory markers
associated with AF are summarized in Table 1.
C-reactive protein. C-reactive protein is the prototype
marker of inflammation and is predominantly synthesized in
hepatocytes as an acute-phase reactant (4). In human
monocytes, CRP not only promotes MCP-1–mediated
chemotaxis by upregulating CC-chemokine receptor 2 ex-
pression, but also induces tissue factor (TF) secretion and
promotes procoagulant activity. Indeed, Chung et al.
(Online Ref. 6) showed an association between serum CRP
and AF, but this was a cross-sectional study and, therefore, did
not address whether inflammatory marker elevation was the
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Finally, CRP has been reported as
a risk factor for recurrences of lone
AF, whereas elevated CRP levels
have been related to AF recur-
rences after successful cardiover-
sion (5).
Aviles et al. (Online Ref. 7)
were the first to demonstrate that
elevated CRP predicted in-
creased risk of developing AF in
a large population-based pro-
spective cohort including 5,806
patients. In another large cohort
study of 47,000 subjects, it was
confirmed that elevated plasma
CRP levels were robustly associ-
ated with increased incidence of
AF (6). Finally in respect to its predictive value, the
combination of clinical risk markers and CRP levels were
significantly associated with the presence of left atrial/left
atrial appendage spontaneous echocardiographic contrast or
thrombus, particularly in patients classified clinically as
having low or moderate risk of stroke (7) (Online Refs.
8–19).
Tumor necrosis factor-. TNF- is a 185 amino acid
lycoprotein peptide hormone that is synthesized mainly by
onocytes and macrophages. It is a pleiotropic proinflam-
atory molecule, and its expression is upregulated in a
ariety of cardiovascular disease settings. There is evidence
upporting the involvement of TNF- in the pathogenesis
f chronic AF. For example, patients with valvular AF
xhibit higher levels of TNF-, more severe leukocyte
infiltration, and more fibrosis than patients with valvular
disease and sinus rhythm (8). Moreover, elevated TNF-
level in the plasma and left atrial tissue had positive
correlation with left atrial diameter in patients with rheu-
Abbreviations
and Acronyms
AF  atrial fibrillation
CABG  coronary artery
bypass graft
CRP  C-reactive protein
IL  interleukin
MCP  monocyte-
chemoattractant protein
MNC  mononuclear cell
sCD40L  soluble CD40L
TF  tissue factor
TNF  tumor necrosis
factor
vWF  von Willebrand
factor
Secretion, Biological Effect, and Prognostic Role of Main InflammaTable 1 Secretion, Biological Effect, and Prognostic Role of M
Inflammatory
Markers Secretion B
IL-2 T lymphocytes 1. Activate T lym
2. Stimulates s
IL-6 Macrophages, T lymphocytes, endothelial cells 1. Stimulate sy
TNF-
2. Recruit leuko
IL-8 Monocytes, macrophages, endothelial cells Activate and re
MCP-1 Monocytes, macrophages Activate and re
lymphocytes
CRP Hepatocytes 1. Promote MC
2. Induce mono
TNF- Monocytes, macrophages Activate immunAF  atrial fibrillation; CRP  C-reactive protein; CV  cardioversion; IFN  interferon; IL  interleukin;
adiofrequency; SEC  spontaneous echocardiographic contrast; TEE  transesophageal echocardiograpmatic heart disease and chronic AF (9). Higher TNF-
levels have been reported in patients with persistent AF
than with paroxysmal AF (10). Finally, a cohort study of
373 patients with chronic nonvalvular AF demonstrated
that TNF- was a significant predictor of ischemic stroke in
-year follow-up (11).
nterleukin-2. Interleukin-2 was the first identified, fully
haracterized, and purified human interleukin. It is pro-
uced mainly by activated T lymphocytes and can activate T
ells and NK cells (12). There are scarce data on the
elationship between IL-2 and AF. Two small-scale pro-
pective studies of patients undergoing cardiopulmonary
ypass graft (CABG), demonstrated that low IL-2 levels
ere associated with reduced incidence of post-operative
F (13) (Online Ref. 20). Moreover, low serum IL-2 levels
n admission were associated with successful pharmaceuti-
al cardioversion in patients with symptomatic recent onset
F (Online Ref. 21).
nterleukin-6. IL-6 is a pleiotropic cytokine with a variety
f biological activities, including mediation of both proin-
ammatory responses and cytoprotective functions. It is
roduced not only by immune cells and immune accessory
ells including monocytes and macrophages, but also by
ardiovascular components, such as endothelial cells, vascu-
ar smooth-muscle cells, and ischemic cardiomyocyte. It
timulates the synthesis of several acute-phase reaction
roteins, such as CRP, serum amyloid-A, and fibrinogen,
nd counterregulates TNF- and IL-1b. Interleukin-6 has
been involved in the generation and perpetuation of AF
(14). High plasma IL-6 levels have been correlated with the
presence and duration of AF and increased left atrial
diameter. In a cross-sectional analysis of 971 coronary heart
disease participants in the Heart and Soul Study, serum
IL-6 was significantly associated with the risk of AF (15).
Finally, several studies have indicated that serum IL-6 levels
are associated with the occurrence of AF post-CABG,
Markers Related to Atrial Fibrillationflammatory Markers Related to Atrial Fibrillation
al Effect Prognostic Role in Atrial Fibrillation Ref. #
ytes
is of TNF-a and IFN-
1. Predictor of early post-operative AF
2. Low serum IL-2 levels on admission
associated with successful CV
(13)
of CRP, fibrinogen, 1. Incidence of AF post-operation
2. Outcome of CV and RF catheter ablation
3. Predictor of stroke and the composite
endpoint of stroke and death in AF
(16–19)
eutrophils, lymphocytes ?
onocytes leukocytes, Incident AF (10)
diated chemotaxis
F secretion
1. Incidence of AF, incidence of LAF or
paroxysmal AF and recurrence after CV
2. Exclude presence of TEE markers:
LA/LAA SEC or LA/LAA thrombus
(6,7,11)
em in AF? Predictor of ischemic stroke (11)toryain In
iologic
phoc
ynthes
nthesis
cytes
cruit n
cruit m
P-1 me
cyte T
e systLA  left atrial; LAA  left atrial appendage; MCP  monocyte-chemoattractant protein; RF 
hy; TF  tissue factor; TNF  tumor necrosis factor.
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December 4, 2012:2263–70 Inflammation in Atrial Fibrillationpost-cardioversion, and after radiofrequency catheter abla-
tion (16–19) (Online Refs. 22–29).
nterleukin-8. IL-8 belongs to the family of CXC chemo-
ines. IL-8 can be synthesized by various cell types, includ-
ng monocytes, macrophages, hepatocytes, fibroblasts, and
ndothelial cells. It is an important activator and a powerful
hemoattractant for neutrophils, thereby promoting
eutrophil-mediated organ injury. IL-8 may aggravate en-
othelial activation and has been directly involved in the
odulation of platelet–platelet and platelet–leukocyte inter-
ctions in a variety of prothrombotic and inflammatory
tates (20). Several clinical studies have reported elevated
L-8 levels in patients with permanent AF.
Studies assessing the association of IL-8 levels with
linical classification/presentation of AF have reported con-
roversial results. For example, Liuba et al. (21) reported
igher IL-8 levels in patients with permanent AF compared
ith patients with paroxysmal AF, whereas De Gennaro et
l. (22) in a case-control study involving 48 consecutive
atients with AF and 58 controls showed that patients with
F duration 6 months had higher level of IL-8 compared
ith AF duration 6 months even after multivariable
orrection for age, sex, and LV ejection fraction.
onocyte chemoattractant protein-1. MCP-1 was the
rst discovered human CC chemokine. The gene encoding
or MCP-1 is located on chromosome 17, and its expression
an be induced by a variety of mediators including platelet-
erived growth factor, IL-1, IL-4, and vascular endothelial
rowth factor. Major sources of MCP-1 are monocytes and
Inflammatory Markers Associated With Subtypes of Atrial FibrillatioTable 2 Inflammatory Markers Associated With Subtypes of At
First Author (Ref. #) Year Subjects AF Subtype
Chung et al. (Online Ref. 6) 2001 131 AF
71 Controls
LAF paroxysmal, perma
Gedikl et al. (Online Ref. 27) 2007 84 AF
30 Controls
New onset AF
Chronic AF (persistent,
permanent)
Liuba et al. (21) 2008 18 AF
10 Controls
Paroxysmal, permanen
Li et al. (10) 2010 305 AF
150 Controls
LAF
Paroxysmal, persistent
permanent
Marcus et al. (25) 2010 167 AF
207 Controls
Paroxysmal
Persistent
Pellegrino et al. (24) 2011 96 AF
60 Controls
LAF
Paroxysmal, persistentACEI  angiotensin-converting-enzyme inhibitor; ARB  angiotensin-receptor blocker; CHF  congestive
tructural heart disease; other abbreviations as in Table 1.acrophages; and MCP-1 exerts potent chemotactic and
ctivating effects on CCR2-positive leukocytes.
Several large cohort studies indicated that serum MCP-1
evels were associated with the risk of atherosclerosis, and
hat they provide independent prognostic value after ACS.
ata linking MCP-1 levels and AF or AF classification/
resentation are nevertheless controversial. In a small case-
ontrol study, MCP-1 has been reported significantly in-
reased during AF, reaching highest levels in patients with
trial thrombi. Accordingly, Li et al. (10) reported that
CP-1 levels were independently associated with AF and
hat there was no significant difference in paroxysmal,
ersistent, and permanent AF. In another cross-sectional
nalysis of 971 participants with coronary artery disease in
he Heart and Soul Study, MCP-1 was not independently
ssociated with AF (15). Similarly, a subanalysis of the
ramingham Study, including 2,863 Framingham Off-
pring Study participants indicated that the inflammatory
iomarkers (including MCP-1) added as a group was
ssociated with incident AF; however, MCP-1 was not
ndependently associated with incident AF in further step-
ise analysis (23) (Online Refs. 30–38).
nflammatory Markers
nd Clinical Presentation of AF
s shown in Table 2, data on the relationship of CRP levels
nd clinical presentation/duration of AF is controversial. In
he cross-sectional study, Chung et al. (Online Ref. 6) first
eported that permanent AF was associated with higher
ibrillation
Markers Results
CRP CRP was higher in permanent AF than paroxysmal AF
hsCRP, IL-6 The hsCRP and IL-6 levels were not different in new onset
and chronic AF
hsCRP, IL-6, IL-8 1. hsCRP and IL-6 levels were not different in paroxysmal
and permanent AF
2. IL-8 was higher in permanent AF than in paroxysmal AF
IL-6, IL-8, IL-10,
TNF-, MCP-1
1. IL-6, IL-8, and MCP1 concentrations were not different in
3 subtypes of AF
2. IL-10 levels were higher in persistent and permanent AF
than in paroxysmal AF
3. A graded increase in TNF- was observed in 3 subtypes
of AF
IL-6, CRP 1. CRP and IL-6 levels were higher in patients with
persistent AF than with paroxysmal AF after adjusting
for age, sex, race, hypertension, CHF, statin, and
ACEI/ARB use
2. CRP and IL-6 level did not remain higher in persistent
versus paroxysmal group after adjusting for rhythm
present during blood draw
CRP 1. CRP levels were higher in patients with paroxysmal than
with persistent AF
2. AF patients with SHD had higher CRP levels than LAF
patients and control subjectsnrial F
nent
t
,heart failure; hsCRP  high-sensitivity C-reactive protein; LAF  lone atrial fibrillation; SHD 
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Inflammation in Atrial Fibrillation December 4, 2012:2263–70levels of CRP than paroxysmal AF, implying that CRP
levels may be related to the burden of AF. On the contrary,
Pellegrino et al. (24) reported significantly increased CRP
levels in subjects with paroxysmal AF compared to subjects
with persistent AF. Interestingly, Marcus et al. (25) found
that CRP and IL-6 levels were significantly higher when
blood was drawn during AF than during sinus rhythm,
regardless of a history of AF.
Liuba et al. (21) assessed IL-6 and high-sensitivity CRP
levels in a small group of patients referred for radiofrequency
catheter ablation, and concluded that there were no differ-
ences in plasma levels of both markers between paroxysmal
AF and permanent AF (21). In accordance with the latter
observation, Gedikli et al. (Online Ref. 27) reported that
high-sensitivity CRP and IL-6 levels did not differ among
new onset and chronic AF patients. In a case-control study
involving 305 patients with AF and 150 controls, Li et al.
(13) found that IL-6, IL-8, and MCP-1 levels were not
different in paroxysmal, persistent, or permanent AF after
adjusting for age, sex, race, body mass index, heart failure,
and statin use; however, the investigators reported higher
TNF- concentrations in patients with persistent AF and in
atients with permanent AF than in patients with paroxys-
al AF. Indeed, a graded increase in TNF- was seen
mong the subgroups of paroxysmal, persistent, and perma-
ent AF, respectively (13). The difference of inflammatory
arkers related to clinical subtypes of AF might be inter-
elated with different role of inflammatory markers in the
athogenesis of AF.
nflammation as a Consequence or Cause of AF?
he role of inflammation in the initiation of AF was
etermined primarily on the basis of the observation that
nflammatory states, such as myocarditis, pericarditis, and
ardiac surgeries, were frequently associated with AF. In-
eed, Shimizu et al. (Online Ref. 39) developed a canine
ericarditis model that demonstrated an increased ability to
ustain AF. Accordingly, higher chance of developing AF
mong patients with clinical pericarditis has been observed.
n a completely different setting, small-scale case-control
tudies showed an inducibility of AF among patients un-
ergoing cardiac surgery (Online Ref. 40). Later, Bruins et
l. (Online Ref. 41) demonstrated that the levels of CRP on
ost-operative day 2 were more elevated in patients that
xperienced post-operative AF than in patients who did not.
hat was further confirmed in a large prospective cohort
tudy of 1,851 patients undergoing CABG in which 33% of
he patients had AF after operation (Online Ref. 42).
urthermore, histological findings of atrial myocarditis (in-
ammatory infiltrates, myocyte necrosis, and fibrosis) were
dentified in patients with lone AF, but not in subjects in
inus rhythm (Online Ref. 43).
Several prospective epidemiological studies confirmed
hat inflammation may confer an increased risk of AF (23).
n a large cohort involving 25,883 participants of the romen’s Health Study, for example, inflammatory bio-
arkers including CRP, soluble intercellular adhesion
olecule-1, and fibrinogen were independently associated
ith increased incidence of AF in initially healthy, middle-
ged women during a median follow-up of 14.4 years, even
fter controlling for traditional risk factors (26). Moreover,
cevedo et al. (Online Ref. 10) demonstrated that CRP
evels of patients with newly diagnosed nonvalvular AF that
emained in AF were elevated compared to those of patients
ho were converted to sinus rhythm, providing evidence
hat inflammation is further implicated in the perpetuation
f AF.
In parallel, an accumulating body of evidence indicates
hat AF might even contribute to inflammation per se.
otter et al. (Online Ref. 8) demonstrated that CRP
eclined in patients with AF after successful ablation.
imilarly Marcus et al. (27) reported elevated CRP and
L-6 serum levels in patients with atrial flutter that signif-
cantly fall after successful ablation. Kallergis et al. (28) also
bserved that high levels of high-sensitivity CRP were
ssociated with an increased risk of AF recurrence after
ardioversion and concluded that inflammation is a conse-
uence, rather than a cause of AF. Whether AF is the cause
r the consequence of inflammation cannot be safely an-
wered on the basis of the available evidence. It is likely that
oth statements are true. Inflammation seems to represent a
otent trigger of AF, whereas AF seems to create and
ustain an inflammatory and prothrombotic environment.
nflammation and AF:
Systemic or Local Phenomenon?
imited data are available on the systemic or local nature of
F-related inflammation. In most cases, the investigators
ried to address this issue by identifying the source of the
nflammatory markers.
Inflammatory markers have been assessed in cardiac
issue, intracardiac blood, and peripheral blood, in AF
atients with or without concomitant structural heart dis-
ase. For example, Liuba et al. (21) showed that patients
ith permanent AF had higher plasma levels of IL-8 in the
amples from the femoral vein, right atrium, and coronary
inus than in the samples from the pulmonary veins,
uggesting that a possible source of inflammation exists in
he systemic circulation. Marcus et al. (25) detected higher
evels of CRP in the left atrium than in the coronary sinus
nd concluded that differences in transcardiac cytokine
radients suggest that AF results in sequestration of inflam-
atory cytokines in the heart.
oes Inflammation Reflect
nderlying Disease or AF Per Se?
few studies have tried to address whether AF or the
nderlying structural heart disease is the cause of the
nflammation. For example, Ellinor et al. (Online Ref. 18)
eported elevated CRP levels in patients with AF and
2267JACC Vol. 60, No. 22, 2012 Guo et al.
December 4, 2012:2263–70 Inflammation in Atrial Fibrillationhypertension compared with those of controls and those of
patients with lone AF. No differences were noted, however,
in CRP levels between patients with lone AF and controls.
Similarly, Pellegrino et al. (24) found higher CRP levels in
AF patients with structural heart disease than lone AF
patients, but CRP levels in lone AF patients were higher
than that seen in controls (non-AF group). Differences
related to the presence of lone AF and structural heart
disease remained significant even after multivariable regres-
sion analysis (24). Thus, further research is required to
clarify whether elevated CRP in AF patients is associated
with underlying cardiovascular disease or the arrhythmia
per se.
Inflammation and AF-Related Thromboembolism
Blood rheology, endothelial dysfunction, coagulation acti-
vation, platelet activation, and increased fibrinolytic activity
may confer a prothrombotic environment in AF (Table 3).
Hemostatic Factors Conferring the Prothrombotic State in Atrial FiTable 3 Hemostatic Factors Conferring the Prothrombotic Stat
First Author (Ref. #) Study Design Subjects
Mondillo et al.
(Online Ref. 57)
Case-control 45 NVAF (chronic AF),
35 controls
Li-Saw-Hee et al.
(Online Ref. 58)
Case-control 20 (chronic AF),
20 vascular disease,
20 controls
Matsubara et al.
(Online Ref. 59)
Case-control 7 NVAF, 4 controls
Marı´n et al. (43) Case-control 90 AF (persistent),
74 controls
Barber et al. (44) Observational cohort 258 AF
Heeringa et al. (45) Longitudinal
population-based
162 AF, 324 SR
Choudhury et al. (46) Case-control 121 AF (paroxysmal,
permanent),
65 healthy controls,
78 diseased controls i
Ohara et al. (41) Case-control 591 NVAF (permanent,
paroxysmal), 129 cont
Conen et al. (26) Prospective cohort 24,734 women without A
(747 had AF during
median follow-up 14.4
Hayash et al. (39) Case-control 14 AF (paroxysmal),
14 chronic AF, 13 con
Rolda´n et al. (42) Prospective cohort 829 AF (permanent) with
AT III  antithrombin III; F12  prothrombin fragment 12; MNC  mononuclear cell; NVAF 
PF  platelet factor; PRP  platelet-rich plasma; PSGL  P-selectin glycoprotein ligand; sICAM  soluble interce
complexes; TF tissue factor; TPA tissue plasminogen activator; vWF von Willebrand factor; other abbreviatioInflammation also plays an important role in the pro-
thrombotic state associated with AF. Proposed mechanisms
linking inflammation to thrombosis include endothelial
activation and/or damage, production of TF from mono-
cytes, increased platelet activation, and increased expression
of fibrinogen (29,30) (Online Refs. 44–49). Activated
inflammatory cells (such as monocytes, resident macro-
phages, and lymphocytes) might trigger and sustain throm-
bosis in AF through the production of cytokines and
chemokines (Fig. 1).
The association of inflammation and AF-related throm-
boembolism was originally supported by the observation
that elevated CRP levels were noted in AF patients with left
atrial and/or left atrial appendage spontaneous echocardi-
ography contrast. Recent studies have further demonstrated
that IL-6 and CRP are markedly elevated in patients with
dilated left atrium and a poorly functioning left atrial
appendage (31). This subgroup of patients is more likely to
tiontrial Fibrillation
Factors Results
Fibrinogen, AT III, PC, PF4,
-thromboglobulin, D-dimer,
TPA, PAI, vWF, soluble
thrombomodulin
There is a correlation among
endothelial dysfunction,
coagulation factors, and left
atrial dimension
vWF, sP-sel, fibrinogen Patients with chronic AF have
increased vWF and fibrinogen
compared with patients in SR
TF TF expression induced by local
inflammation is involved in
the pathogenesis of
thrombosis in AF
Factor XIII Val34Leu, TF, sP-sel,
fibrinogen
Factor XIII Val34Leu
polymorphism was
independently associated with
IL-6 levels in AF
Fibrinogen, D-dimer, F12, TAT,
vWF, TPA
Thrombin generation and fibrin
turnover were increased in AF
VWF, sP-sel, fibrinogen sP-sel predicted clinical adverse
outcomes in AF
CD62P, CD63, sP-sel, lysate
P-selectin
Platelet activation in AF may be
due to underlying
cardiovascular disease, rather
than due to AF
PF4, -thromboglobulin, F12,
D-dimer
Coagulation and fibrinolytic
activity is increased along with
accumulation of the risk
factors of TE in NVAF
CRP, sICAM-1, fibrinogen Inflammation, as jointly measured
by plasma levels of hsCRP,
sICAM-1, and fibrinogen, is
significantly associated with
risk of incident AF
CD41a, CD42b, P-selectin,
PSGL-1, microparticles in PRP
Patients with chronic AF showed
platelet-MNC interaction ex
vivo and TF over-expression
on MNCs
vWF, D-dimer vWF is associated with thrombotic
events and bleeding in AF
ular atrial fibrillation; OAC oral anticoagulant; PAI plasminogen activator inhibitor; PC protein C;brillae in A
n SR
rols
F
yrs)
trols
OAC
nonvalv
llular adhesion molecule; sP-sel  soluble P-selectin; SR  sinus rhythm; TAT  thrombin-antithrombin
ns as in Tables 1 and 2.
S
m
s
f
p
d
m
a
a
t
l
p
t
t
I
p
a
C
e
m
a
o
c
n
d
s
p
b
p
w
r
l
C
o
f
2268 Guo et al. JACC Vol. 60, No. 22, 2012
Inflammation in Atrial Fibrillation December 4, 2012:2263–70have spontaneous echocardiography contrast and/or throm-
bus in the left atrial appendage. Of note, patients with
longer duration of AF had a greater elevation in CRP levels
and subsequently greater atrial structural remodeling, as
evident by larger left atrial diameter. Moreover, CRP has
been further shown to positively correlate with established
clinical stroke risk stratification schemas (CHADS2,
PAF), with the highest CRP levels seen among patients at
oderate to high risk for stroke. Similarly, IL-6 was found
ignificantly higher in AF patients with traditional risk
actors for stroke, but also was proved an independent
redictor of stroke and the composite endpoint of stroke or
eath in long-term follow-up.
Altered endothelial function also contributes to inflam-
ation and thrombosis in AF (32,33). Upon endothelial
ctivation, substances such as vWF and soluble P-selectin
re rapidly released onto the endothelial surface, promoting
he attachment of rolling white blood cells to the endothe-
ium and subsequently contributing to the development of a
roinflammatory and prothrombotic environment.
Other inflammatory cytokines are also plausible media-
ors to the prothrombotic state. For example, IL-6 induces
Figure 1 Proposed Mechanism Linking Inflammation and Throm
Activated inflammatory cells (such as monocytes, macrophages, and lymphocytes)
Activated lymphocytes synthesize interleukin (IL)-2 and IL-6, while monocyte and m
sis factor-alpha (TNF). Interleukin-6 stimulates the synthesis of fibrinogen and en
tor (vWF) and P-selectin. Mononuclear cell–platelet interactions through soluble P-s
mononuclear cells. Activated platelets in atrial fibrillation (AF) patients induce the
ways. CRP  C-reactive protein; F12  prothrombin fragment 12; PAI  plasm
complexes.he expression of TF, fibrinogen, factor VIII, and vWF. cndeed, a strong correlation has been observed between
lasma IL-6 and TF levels in blood obtained from the right
nd left atria of AF cases during cardiac catheterization.
-reactive protein may also exert a systemic deleterious
ffect on endothelial cells; CRP promotes MCP-1–
ediated chemotaxis, and induces monocyte TF secretion
nd procoagulant activity. Endothelial injury can also induce
verexpression of TF and vWF, activating the coagulation
ascade.
Inflammatory markers, such as IL-6, have been linked
ot only to endothelial activation and endothelial cell
amage, but also to increased platelet aggregation and
ensitivity to thrombin (30). Activated platelets in AF
atients could, in turn, promote and sustain the prothrom-
otic state and increase inflammatory biomarkers. Indeed,
latelets are the main source of soluble CD40L (sCD40L),
hich can induce TF expression through binding to its
eceptor CD40 on the leukocytes. The mechanisms under-
ying platelet-leukocyte interaction through the CD40-
D40L pathway in AF remain unclear, but increased levels
f sCD40L exacerbate platelet aggregation and thrombus
ormation (34,35). Moreover, sCD40L levels are signifi-
in AF
r endothelial dysfunction, platelet activation, and increase fibrinogen production.
hage produce IL-8, monocyte-chemoattractant protein (MCP)-1, and tumor necro-
s the expression of tissue factor (TF). Interleukin-8 increases von Willebrand fac-
n (sP-sle)–P-selectin glycoprotein ligand (PSGL)-1 result in TF overexpression on
tion of inflammatory biomarkers (MCP-1) through CD40-CD40L–mediated path-
activator inhibitor; PF4  platelet factor 4; TAT  thrombin-antithrombinbosis
trigge
acrop
hance
electi
produc
inogenantly increased in patients with AF (36). Levels of
i
p
i
s
t
t
p
t
p
m
w
l
r
b
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paroxysmal/persistent AF but not in patients with AF
relapse.
Platelet CD40 expression was shown to remain elevated
even 5 weeks after successful cardioversion, which may
imply a persistently increased risk for atrial thrombus
formation. Pre-operative sCD40L levels independently pre-
dicted post-CABG AF and sCD40L has been reported to
have a significant predictive value for future stroke and
contributes to the pathophysiology of atherosclerosis and
atherothrombosis (37–39) (Online Refs. 50–53).
The vascular adhesion molecules P-selectin and its ligand
P-selectin glycoprotein ligand (PSGL)-1 have important
roles in the interactions between platelets and monocytes or
polymorphonuclear cells during thrombus formation.
Hayashi et al. (39) demonstrated that acute induction of AF
significantly increased the expression of P-selectin on plate-
lets and microparticles, and to a similar extent, P-selectin–
positive monocytes and granulocytes and P-selectin/
PSGL-1 double positive monocytes. However, only patients
with chronic AF showed platelet-monocyte interaction ex
vivo and TF overexpression on monocytes. These research-
ers concluded that acute-onset AF activates platelets within
minutes to initiate platelet-monocyte interaction (39).
Inflammation and AF: A New Therapeutic Target?
The accumulation of evidence supporting a link between inflam-
mation and AF generated the hypothesis that pharmacological
interventions with pleiotropic/anti-inflammatory effects might be
efficacious in the prevention of AF by modulating inflammatory
pathways (Online Refs. 54–56). Several studies have addressed
this issue, with controversial results. In the largest randomized,
placebo-controlled, multicenter study that tested the hypothesis,
Almroth et al. (40) evaluated the effect of 80 mg of atorvastatin in
achieving sinus rhythm 30 days after electrical cardioversion in 234
patients with persistent AF. An intention-to-treat analysis showed
that 51% of the patients in the atorvastatin group and 47% in the
placebo group were in sinus rhythm 30 days after cardioversion;
nevertheless, this difference did not reach the cutoff point of
statistical significance (40).
Finally, the discovery of a single inflammatory marker or
nflammatory pathway that is responsible for AF would
rovide promising potential therapies for AF. However, as
s the case in most inflammation-related human diseases, a
ingle-marker approach is a utopian. Only a few inflamma-
ory markers have been studied for AF until now. Moreover,
hese markers have been assessed separately in different
opulations with different disease profiles. Perhaps a mul-
imarker approach to a wide range of AF patients might
rovide better insights in this field. Finally, beyond inflam-
ation, serologic markers of fibrosis have been associated
ith AF. Fibrosis and inflammation are strongly interre-
ated and share common pathways. Nevertheless, a detailed
eview of markers of fibrosis and their impact on AF was
eyond the scope of the present paper.Quo Vadis?
Inflammation seems to play an important role in the
prothrombotic state associated with AF. Inflammatory
markers measured in peripheral blood seem to correlate well
with clinical and echocardiographic risk factors of throm-
boembolism. However, the important question is how these
clinical-research data can be translated into clinical practice.
One area may be risk stratification in AF, and inflammatory
biomarkers could potentially refine clinical risk stratification
for stroke and thromboembolism. However, both the sam-
ple sizes and the effect sizes reported in available studies do
not support the routine clinical use of inflammatory bio-
markers in AF management. Few studies have assessed the
importance of inflammatory biomarkers in predicting di-
rectly hard endpoints such as stroke and mortality.
Further studies with large sample sizes and hard endpoints
are needed to assess the clinical importance of inflammatory
biomarkers in AF. If such studies are ever designed, they
should address the additive value of inflammatory biomarkers
against well-established clinical, demographic, and echocardio-
graphic risk factors of thromboembolism.
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